文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克危重患者不同剂量维生素B1治疗策略比较

Comparison of Variable Thiamine Dosing Strategies in Critically Ill Patients with Septic Shock.
PubMed 文献 · Shock · 2025-10-16
一句话结论回顾性队列显示脓毒性休克患者高剂量与低剂量维生素B1在升压药无升压药存活天数上无统计学差异,需更大前瞻性随机试验进一步研究。

该回顾性队列研究纳入脓毒性休克患者,比较高剂量(>500 mg/d)与低剂量(≤500 mg/d)维生素B1治疗72小时对升压药无升压药存活天数的影响。高剂量组87例,低剂量组65例,高剂量组平均剂量1485.6 mg/d,低剂量组323.8 mg/d。两组升压药无升压药存活天数分别为17.13天与14.84天,28天死亡率、ICU住院时长、无升压药天数、乳酸或血清肌酐下降百分比、需额外升压药及住院时长均无统计学差异。作者结论认为需更大规模前瞻性随机试验进一步研究高剂量维生素B1在脓毒性休克危重患者中的作用。

要点

  • 脓毒性休克患者高剂量维生素B1(>500 mg/d)与低剂量(≤500 mg/d)相比,升压药无升压药存活天数分别为17.13天与14.84天,无统计学差异。
  • 两组28天死亡率、ICU住院时长、无升压药天数、乳酸或血清肌酐下降百分比、需额外升压药及住院时长均无统计学差异。
  • 高剂量组平均维生素B1剂量为1485.6 mg/d,低剂量组为323.8 mg/d,治疗时长72小时。
  • 高剂量组更常使用30 mL/kg静脉液体复苏(89% vs. 82%)及氢化可的松300 mg/d(69% vs. 58%)。
  • 作者结论认为需更大规模前瞻性随机试验进一步研究高剂量维生素B1在脓毒性休克危重患者中的作用。

适用人群与场景

  • 脓毒性休克成人患者,使用高剂量(>500 mg/d)或低剂量(≤500 mg/d)维生素B1治疗72小时且无其他适应症。

处置流程与药物剂量

  • 高剂量维生素B1:>500 mg/d,平均1485.6 mg/d,疗程72小时。
  • 低剂量维生素B1:≤500 mg/d,平均323.8 mg/d,疗程72小时。
  • 高剂量组更常使用30 mL/kg静脉液体复苏(89% vs. 82%)及氢化可的松300 mg/d(69% vs. 58%)。

研究设计与关键结果

  • 回顾性队列研究,纳入87例高剂量组和65例低剂量组脓毒性休克患者。
  • 主要终点升压药无升压药存活天数:高剂量组17.13天 vs. 低剂量组14.84天,无统计学差异。
  • 28天死亡率、ICU住院时长、无升压药天数、乳酸或血清肌酐下降百分比、需额外升压药及住院时长均无统计学差异。
  • 部分观察到的差异被认为具有临床意义。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为需更大规模前瞻性随机试验进一步研究高剂量维生素B1在脓毒性休克危重患者中的作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Thiamine has been utilized for metabolic resuscitation in septic shock (SS), but optimal thiamine dosing remains unknown. The purpose of this study was to assess variable thiamine dosing in critically ill patients with SS.

METHODS: This retrospective, cohort study included SS patients on high-dose (HD >500 mg/d) or low-dose (LD ≤500 mg/d) thiamine for 72 hours without an alternative indication. The primary endpoint was to evaluate the impact of HD or LD thiamine on vasopressor alive-and-free days.

RESULTS: The analysis included 87 patients who received HD thiamine and 65 patients who received LD thiamine. The mean thiamine dose was 1.485.6 mg/d in the HD group and 323.8 mg/d in the LD group. The HD group more often utilized 30 mL/kg of intravenous fluid resuscitation (89% vs. 82%) and hydrocortisone at 300 mg/d (69% vs. 58%). Results found vasopressor alive-and-free days to be 17.13 in the HD group and 14.84 days in the LD group. No statistically discernible differences were found between the groups in 28-day mortality, intensive care unit length of stay, vasopressor free days, percentage decrease in lactate or serum creatinine, need for additional vasopressor(s), or hospital length of stay, although some of the observed differences are believed to be clinically meaningful.

CONCLUSION AND RELEVANCE: Patients with SS who received HD thiamine had no statistically discernible differences in vasopressor alive-and-free days or intensive care unit length of stay as compared to the LD thiamine group. Larger, prospective, randomized trials are warranted to further investigate HD thiamine in critically ill patients with SS.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Maier A, Kolar R, Shible A, et al. Comparison of Variable Thiamine Dosing Strategies in Critically Ill Patients with Septic Shock. Shock. 2025. PMID: 41166064. doi:10.1097/SHK.0000000000002739

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。